As CD38 upregulation has been considered a possible mechanism of acquired resistance to CPI therapy in patients with melanoma (8), it is possible that greater levels of CD38 expression are a prerequisite for modakafusp alfa activity in this setting. Here, CD38 is linked to melanoma.